# FLAURA2 (NCT04035486)

> A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04035486
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Osimertinib; Pemetrexed/Carboplatin; Pemetrexed/Cisplatin
- Enrollment: 587
- Primary outcome: Adverse Events Graded by Common Terminology Criteria for Adverse Event v5 (Safety Run-In Treatment Arms Only)
- Primary outcome: Progression-free Survival (PFS) (Randomized Component)
- Primary outcome: Sensitivity Analysis for Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Randomized Component)

## Commentary we found

- X threads: 528
- YouTube: 117
- Podcasts: 107
- X videos: 6

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=flaura2-nct04035486

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04035486", "email": "<work email>"}; the inbox owner confirms by the emailed link.